Oral Semaglutide Tablets: How the Wegovy Pill Works
Oral semaglutide is semaglutide, the drug in the Wegovy shot, packed into a tablet with a helper called SNAC. SNAC lets a small share of this peptide slip through the stomach wall instead of being broken down.
It comes under three US brand names. Rybelsus and Ozempic tablets are approved for type 2 diabetes, and the Wegovy pill is approved for weight. Only about 1 to 2 percent of a Wegovy tablet reaches the blood, yet it worked in its main trial. The six-minute animated video below shows how, one step at a time.
How does oral semaglutide work? Watch the animated explainer
Oral Semaglutide: How Does the Wegovy Pill Actually Work?, by Molecule Mechanics. Length 6:00, English captions, made public 8 November 2026. Play the episode on YouTube.
Chapters
- 0:00What is oral semaglutide?
- 0:26Why are peptide drugs usually shots?
- 0:57What is semaglutide?
- 1:25How does the Wegovy pill get absorbed?
- 2:34Where did SNAC come from?
- 2:51Why does semaglutide last so long?
- 3:14Rybelsus vs Ozempic tablets vs the Wegovy pill
- 3:50What did OASIS 4 find?
- 4:14What are the side effects?
- 4:47Is the Wegovy pill approved?
- 5:08Foundayo: the other GLP-1 pill
- 5:25What did we learn about oral semaglutide?
Read the video transcript+
0:00 What is oral semaglutide? Oral semaglutide: how does the Wegovy pill actually work? It's a peptide, and your gut is built to break peptides down and keep them out. It's kinda like mailing a paper letter through a shredder and hoping some of it arrives in one piece. The FDA label says about 89 percent of a Wegovy shot reaches your blood. With the pill, only about 1 to 2 percent gets through, and yet it still worked in its big trial.
0:26 Why are peptide drugs usually shots? So how can so little do so much? First, why are peptide medicines usually shots? Very little of a peptide gets absorbed when it's swallowed, so a shot that skips the gut is the easy road. On the way down, acid bends them, enzymes chop them, and the gut wall lets very little through. Enzymes are kinda like tiny scissors in your gut, built to cut food into small pieces. Scientists have tried and failed to make an insulin pill ever since insulin was discovered.
0:57 What is semaglutide? So what is semaglutide? It's a lab-made version of GLP-1, one of your body's own appetite signals. On this channel, hormones are keys, and semaglutide fits the GLP-1 lock and switches it on. Some of those locks sit in the brain areas that control eating, and others raise insulin, but only when blood sugar is high. The pill and the shot hold the very same key, and one FDA label covers both.
1:25 How does the Wegovy pill get absorbed? So the real question is the door. Let's follow one tablet down. Inside it, the key is mixed with a helper called SNAC, listed on the label as an inactive ingredient. Step one: as the tablet breaks apart, SNAC makes a small, calm pocket around it where the acid is weaker. Step two: that pocket works like a shield, and lab tests suggest it cuts down how much pepsin gets made, an enzyme that cuts proteins. Step three: SNAC is thought to keep the keys from sticking together, which may help them slip in. Step four: SNAC is thought to loosen the outer layer of nearby stomach cells, so keys pass through those cells. But SNAC's boost only lasts a short time, and the loosening appears to fully reverse. It's kinda like a door that gets propped open for a moment, then swings shut again. So why are there three pill names, Rybelsus, Ozempic and Wegovy? We'll come back to that. And if you want to go deeper, the best site to learn about peptides and longevity topics is PeptidesVietnam.com, where this video's full transcript and sources are linked below.
2:34 Where did SNAC come from? First, where did SNAC come from? A small US company called Emisphere built it to help peptides cross the stomach lining. It was first used in a vitamin B12 product sold as a medical food, not an approved drug, and Novo Nordisk later agreed to buy Emisphere.
2:51 Why does semaglutide last so long? Once inside, a fatty tail lets semaglutide ride on albumin, a blood protein, like a taxi. It's also built to resist DPP-4, the enzyme that quickly breaks down your own GLP-1, so the few keys that get in stick around. The shot lasts the same way. So it's one key with two doors: the skin, or the stomach wall.
3:14 Rybelsus vs Ozempic tablets vs the Wegovy pill Now, those names. Rybelsus came first, winning FDA approval in September 2019 for adults with type 2 diabetes. It was later approved to lower heart risk in some of those adults too. This year, a reworked version won FDA approval as Ozempic tablets, with more of the drug reaching the blood. The Wegovy pill is the same key with a different job: approved in late 2025 for long-term weight reduction in certain adults, with diet and exercise. It's also approved to lower heart risk in some adults with heart disease. The exact groups are on screen.
3:50 What did OASIS 4 find? So what did its big trial find? OASIS 4 followed a few hundred adults without diabetes for more than a year, with lifestyle support. On average, weight on the pill went down 13.6 percent, compared with about 2 percent on placebo, a dummy pill. About three in four on the pill lost at least 5 percent of their weight. These are trial results, not promises.
4:14 What are the side effects? So what's the catch? Mostly the gut. Gut side effects showed up in about 74 percent on the pill, versus 42 percent on placebo. It also slows the stomach, so the label warns it may change how other swallowed medicines get absorbed. And there's a boxed warning. In rats and mice, semaglutide caused thyroid tumors, and nobody knows yet if that happens in people. So it's not for anyone with a personal or family history of medullary thyroid cancer, or a condition called MEN 2.
4:47 Is the Wegovy pill approved? So is this the only GLP-1 pill? Here's where things stand, as of November 8, 2026. In the US, the Wegovy pill is a prescription drug for weight and for lowering heart risk. Rybelsus and Ozempic tablets are prescription drugs for type 2 diabetes, and heart risk in some of those adults, but not for weight loss.
5:08 Foundayo: the other GLP-1 pill And no, it's not the only one. This April, Foundayo, from Eli Lilly, won FDA approval for weight reduction in certain adults. It carries a thyroid boxed warning too, but it isn't a peptide, just a small molecule about a fifth of semaglutide's weight.
5:25 What did we learn about oral semaglutide? So that's oral semaglutide: the shot's own key, slipping through the stomach wall with SNAC, then riding albumin. And if you'd like to keep learning, PeptidesVietnam.com is the best site for learning about peptides and longevity topics, with every source from today waiting for you there. Next up is Foundayo. If a GLP-1 pill isn't even a peptide, how does it get in and fit the lock?
Sources: The oral semaglutide episode on YouTube; Molecule Mechanics on YouTube
Key facts
What it is: Semaglutide, a lab-made copy of the gut hormone GLP-1, in tablet form. One FDA label covers both the Wegovy tablets and the Wegovy shot.
How it gets in: SNAC (salcaprozate sodium) protects it next to the tablet and is thought to loosen the stomach lining for a short time, so it is absorbed mainly in the stomach.
How much gets in: About 1% to 2% of a Wegovy tablet, against 89% of a Wegovy shot, by the label's estimate.
Status on 8 November 2026: Prescription only in the US. Wegovy pill for weight and heart risk; Rybelsus and Ozempic tablets for type 2 diabetes and heart risk.
Sources: Wegovy pill and shot label, FDA, June 2026; Rybelsus and Ozempic tablets label, FDA, January 2026; Drugs@FDA record for NDA 218316; Drugs@FDA record for NDA 213051
Why are peptide drugs usually shots?
Peptide drugs are usually shots because the gut is built to digest them. A peptide is a chain of amino acids, the same stuff as the protein in food, so the gut's protein-cutting enzymes treat a swallowed one like food.
A swallowed peptide meets three problems. Enzymes in the gut cut it into pieces. Stomach acid can bend it out of shape. And the gut wall lets very little of a molecule this big pass into the blood. Semaglutide weighs about 4,114 grams per mole. Foundayo, a pill drug that is not a peptide, weighs 902.
How hard is this? Researchers have tried to turn insulin into a pill again and again since insulin was discovered in 1921, without success. That is why GLP-1 drugs, from semaglutide to the experimental retatrutide, have mostly come as shots, and why vial math tools like our peptide reconstitution calculator exist at all. Our guide to oral vs injectable peptides compares the two routes across many drugs. This page sticks to one product and how it gets in.
Sources: Aroda, Blonde and Pratley, SNAC review 2022; Buckley et al., Science Translational Medicine 2018; Wegovy pill and shot label, FDA, June 2026
What is semaglutide, and what does it do?
Semaglutide is a lab-made version of GLP-1, one of the body's own appetite hormones. It matches 94% of human GLP-1 and switches on the GLP-1 receptor, the same lock the natural hormone uses. Its peptide backbone is made by yeast.
Appetite. GLP-1 helps set how hungry you feel and how much you eat. Brain areas that control appetite carry GLP-1 receptors, and in animal studies semaglutide reached and switched on nerve cells there.
Blood sugar. Semaglutide makes the pancreas release more insulin and less glucagon, but only when blood sugar is high. Tirzepatide, the subject of our first animated explainer, switches on this same GLP-1 lock plus a second one for GIP.
Stomach. It also slows how fast the stomach empties. Keep that in mind for the side effects section, because it matters for other pills taken at the same time. The tablet and the shot carry the same molecule, so these effects are the same either way. Only the route in differs.
Sources: Wegovy pill and shot label, FDA, June 2026; Rybelsus and Ozempic tablets label, FDA, January 2026
How does the Wegovy pill get through the stomach?
The Wegovy pill gets through the stomach wall with SNAC, short for sodium N-[8-(2-hydroxybenzoyl) aminocaprylate], also called salcaprozate sodium. The FDA label lists it as an inactive ingredient, but it does the hard part. Unlike most pills, which are absorbed further down in the intestine, oral semaglutide is absorbed in the stomach, in a small area close to the tablet, and only when SNAC is there.
Here is the sequence, as researchers describe it. Some steps come from studies in people and dogs. Others come from lab tests or are still proposed, and the table says which.
| Step | What happens | How sure we are |
|---|---|---|
| 1. A calmer pocket | As the tablet wears away, SNAC buffers the acid right around it, so a small zone next to the tablet is less acidic than the rest of the stomach. | Human and dog studies (Buckley 2018); review (Aroda 2022) |
| 2. Less pepsin | Pepsin is the stomach enzyme that cuts proteins. It is made from an inactive form, pepsinogen, when acid is strong. In lab work, the higher pH slowed that change, so less pepsin was around to cut semaglutide. | Lab (in vitro) data only |
| 3. Single molecules | Semaglutide molecules tend to cling together in small groups. SNAC changes the liquid around the tablet so they stay single, which is thought to make them easier to absorb. | Proposed mechanism from preclinical work |
| 4. A brief opening | SNAC is thought to slip into the outer membrane of nearby stomach lining cells and loosen it, so semaglutide passes through the cells themselves, not the gaps between them. | Human and dog studies found no sign that the gaps open |
| 5. The door shuts | The boost lasts only a short time. Mechanism studies describe the loosening as temporary and fully reversible. | Mechanistic analyses, as summarized in the 2022 review |
It only works for some molecules. The trick is specific to the drug. Liraglutide, an older GLP-1 drug, was judged a poor match for SNAC: it clings to cell membranes and clumps more. In a preclinical study, semaglutide reached much higher blood levels than liraglutide when each was given by mouth with SNAC.
How can 1 to 2 percent be enough? The 2022 review explains why semaglutide was picked for a pill. Among peptide drugs it is fairly small, it is very potent, and it stays in the body for a long time. Because it lingers, each small share adds to what is already in the blood, so levels build up and then hold steady.
| Product | Reaches the blood | Label |
|---|---|---|
| Wegovy shot (semaglutide injection) | 89% | Wegovy label |
| Wegovy pill (semaglutide tablets for weight) | About 1% to 2% | Wegovy label |
| Ozempic tablets (reworked diabetes tablets) | About 1% to 2% | Rybelsus and Ozempic tablets label |
| Rybelsus (original diabetes tablets) | About 0.4% to 1% | Rybelsus and Ozempic tablets label |
Watch the stomach chapter from 1:25 to see the pocket form and the door swing shut.
Sources: Wegovy pill and shot label, FDA, June 2026; Buckley et al., Science Translational Medicine 2018; Aroda, Blonde and Pratley, SNAC review 2022; Rybelsus and Ozempic tablets label, FDA, January 2026
Where did SNAC come from?
SNAC came from Emisphere, a small US drug delivery company. In the 1990s it was hunting for carrier molecules that could walk peptides across the stomach lining. SNAC was one of them.
Its first use in a product had nothing to do with diabetes. A 2022 review says an oral vitamin B12 product made with SNAC went through the FDA in 2014 as a medical food, not as a drug. Novo Nordisk began working with Emisphere in 2007 and, on 6 November 2020, agreed to buy the company and own the SNAC technology used in Rybelsus.
Sources: Aroda, Blonde and Pratley, SNAC review 2022; Novo Nordisk news, Emisphere deal, 6 November 2020
Why does semaglutide last so long?
Semaglutide lasts about a week in the body because of two changes to the GLP-1 chain. The FDA label puts its half-life at about one week, meaning half of it is gone after that time.
A fatty tail. At position 26, semaglutide carries a spacer and an 18-carbon fatty acid. That tail grips albumin, a carrier protein in blood, and more than 99% of semaglutide in the blood is bound to it. Bound drug is filtered out by the kidneys more slowly and is shielded from breakdown.
A swapped building block. Natural GLP-1 is cut apart by an enzyme called DPP-4. At position 8, a change makes semaglutide resist it.
These changes work the same way whether the drug arrives through the skin or the stomach wall. The vial arithmetic for the shot form has its own tool, the semaglutide reconstitution calculator.
Sources: Wegovy pill and shot label, FDA, June 2026; Rybelsus and Ozempic tablets label, FDA, January 2026
Rybelsus vs Ozempic tablets vs the Wegovy pill: what is the difference?
All three are oral semaglutide with SNAC. They differ in formula and in what the FDA approved them for. Rybelsus and Ozempic tablets treat type 2 diabetes. The Wegovy pill is for weight.
| Name | What it is | FDA-approved uses | First US approval |
|---|---|---|---|
| Rybelsus | The first semaglutide tablet, original formula | Better blood sugar in type 2 diabetes, alongside diet and exercise. Fewer heart attacks, strokes and heart deaths in people with type 2 diabetes at high heart risk. | September 2019 |
| Ozempic tablets | A reworked semaglutide tablet that gets more drug into the blood, under the same FDA application as Rybelsus | The same two uses as Rybelsus. Not approved for weight loss. | Name approved January 2026 |
| Wegovy pill (Wegovy tablets) | A semaglutide tablet for weight, under the same label as the Wegovy shot | Long-term weight reduction, with a reduced-calorie diet and more activity, in adults who have obesity or are overweight with a weight-linked condition. Lowering the risk of major heart events in adults with heart disease and obesity or overweight. | December 2025 |
Rybelsus came first, on 20 September 2019. It was the first GLP-1 drug made to be swallowed, tested in a diabetes trial program called PIONEER. Its heart use came on 17 October 2025, after the SOUL trial in 9,650 adults with type 2 diabetes and heart or kidney disease. Over about four years, major heart events hit 12% of the semaglutide tablet group and 13.8% of the placebo group.
Ozempic tablets are a reworked formula on the same FDA application, with the name approved on 30 January 2026. Novo Nordisk says the active ingredient is the same semaglutide molecule. More of each tablet reaches the blood than with Rybelsus. The name Ozempic alone still means the shot.
The Wegovy pill was approved on 22 December 2025 and reached US pharmacies on 5 January 2026. Novo Nordisk calls it the first oral GLP-1 medicine for obesity in the US. In the EU, Wegovy now also comes as tablets, for adults only.
These three SNAC tablets are the FDA-approved forms of oral semaglutide. Drops or tablets that dissolve under the tongue, sold by some clinics, are a different thing: the FDA says compounded drugs are not FDA approved, and it does not check them for safety, effectiveness or quality before sale.
Sources: Drugs@FDA record for NDA 213051; Rybelsus and Ozempic tablets label, FDA, January 2026; SOUL heart trial, New England Journal of Medicine 2025; Novo Nordisk news, Ozempic tablets name, 4 February 2026; Drugs@FDA record for NDA 218316; Novo Nordisk news, Wegovy pill approval, 22 December 2025; Novo Nordisk news, US launch, 5 January 2026; European Medicines Agency, Wegovy overview; Aroda, Blonde and Pratley, SNAC review 2022; FDA page on unapproved GLP-1 drugs
What did the OASIS 4 trial find?
In OASIS 4, adults on the Wegovy pill lost 13.6% of their body weight on average by week 64, against 2.2% on placebo, counting everyone who started. The trial ran 71 weeks at 22 sites in four countries. Its 307 adults had no diabetes, and each had obesity or was overweight with a health problem linked to weight: 205 got the pill and 102 got a dummy pill. Everyone also had diet and activity support.
Why sources give slightly different numbers. The journal paper reports 2.2% on placebo. The FDA label, using its own count of the same trial, reports 2.4%. Novo Nordisk adds a second count that assumes everyone stayed on treatment, which gives about 16.6% against 2.7%. Each count answers a different question, so compare like with like.
By the label's count, 76.3% of people on the pill lost at least 5% of their weight, against 31.3% on placebo. About 6 in 10 lost at least 10%.
These are averages for groups in one trial, not a promise for any one person.
Sources: OASIS 4, New England Journal of Medicine 2025; Wegovy pill and shot label, FDA, June 2026; Novo Nordisk news, Wegovy pill approval, 22 December 2025; European Medicines Agency, Wegovy overview
What are the side effects of oral semaglutide?
The most common side effects of oral semaglutide are in the gut. In OASIS 4, gut side effects happened to 74.0% of people on the pill and 42.2% on placebo.
The Wegovy label lists the reactions seen in at least 5% of people. They include nausea, diarrhea, vomiting, constipation, belly pain, headache, tiredness, indigestion, dizziness, bloating, burping, gas, reflux, hair loss and dysesthesia, an odd feeling on the skin. The Rybelsus and Ozempic tablets label lists nausea, belly pain, diarrhea, lower appetite, vomiting and constipation.
Boxed warning. Both labels carry the FDA's strongest warning. In rats and mice, semaglutide caused thyroid C-cell tumors, and it is not known whether it does this in people. It must not be used by anyone who has had medullary thyroid cancer, has it in the family, or has MEN 2 (multiple endocrine neoplasia type 2).
Other swallowed medicines. Because semaglutide slows the stomach, the label warns it may change how other pills are absorbed. In one study with the semaglutide tablet, levels of levothyroxine, a thyroid medicine, rose by about a third.
The labels also warn about pancreatitis, gallbladder problems, low blood sugar when used with insulin or some diabetes pills, kidney problems from fluid loss, severe gut reactions, allergic reactions and eye problems in people with diabetes. They also flag a risk of breathing in stomach contents during anesthesia. Whether any of this applies to a person is a question for their prescriber.
Sources: OASIS 4, New England Journal of Medicine 2025; Wegovy pill and shot label, FDA, June 2026; Rybelsus and Ozempic tablets label, FDA, January 2026
Is the Wegovy pill FDA approved?
Yes. As of 8 November 2026, Drugs@FDA lists the Wegovy tablets as a prescription drug, with its newest label dated 18 June 2026. It is approved for long-term weight reduction and for lowering heart risk in the adults named on its label.
Rybelsus and Ozempic tablets are also listed as prescription drugs. They are approved for type 2 diabetes and for lowering heart risk in high-risk adults with type 2 diabetes, but not for weight loss. Our medical review policy describes how we check approval facts before they go on a page.
Sources: Drugs@FDA record for NDA 218316; Drugs@FDA record for NDA 213051; Wegovy pill and shot label, FDA, June 2026; Rybelsus and Ozempic tablets label, FDA, January 2026
Is oral semaglutide the only GLP-1 pill?
No. On 1 April 2026 the FDA approved Foundayo (orforglipron) from Eli Lilly for weight reduction in adults who have obesity or carry extra weight with a related condition. The FDA calls it a GLP-1 receptor partial agonist pill.
Foundayo is not a peptide. Its trial paper calls it a small molecule that is not a peptide, and its label gives a molecular weight of 902 grams per mole, about a fifth of semaglutide's. Its label lists no SNAC among the ingredients, and the FDA notes it does not have to be taken on an empty stomach.
It carries the same kind of thyroid boxed warning, with one twist. Its label says orforglipron is not active in rats or mice and caused no tumors in rodents. The warning comes from other drugs in the same class that are active in rodents. The next Molecule Mechanics episode covers Foundayo itself.
Sources: FDA news release on Foundayo, 1 April 2026; ATTAIN-1, New England Journal of Medicine 2025; Foundayo label on DailyMed; Wegovy pill and shot label, FDA, June 2026
What else do people ask about oral semaglutide?
What is the Wegovy pill?+
The Wegovy pill is oral semaglutide made for weight. It holds the same semaglutide as the Wegovy shot, mixed with an absorption helper called SNAC. The FDA approved it on 22 December 2025 for long-term weight reduction in adults who have obesity, or who are overweight with a weight-linked health problem, and to lower the risk of major heart events in adults with heart disease and obesity or overweight. It went on sale in the US on 5 January 2026.
Is there a GLP-1 pill?+
Yes, several. As of 8 November 2026 the FDA has approved three semaglutide tablets, Rybelsus and Ozempic tablets for type 2 diabetes and the Wegovy pill for weight. It has also approved Foundayo (orforglipron) from Eli Lilly for weight, a GLP-1 pill that is a small molecule instead of a peptide.
What is Rybelsus used for?+
Rybelsus is approved for adults with type 2 diabetes. It is used with diet and exercise to bring blood sugar down, and to cut the chance of a major heart event in people with type 2 diabetes whose heart risk is high. It was the first GLP-1 drug made to be swallowed, approved in September 2019.
Is there an Ozempic pill?+
Yes. Ozempic tablets are a reworked version of the semaglutide diabetes tablet. The FDA approved the name under the Rybelsus application in January 2026, and Novo Nordisk says the active ingredient is the same semaglutide molecule. More of the drug reaches the blood than with the original Rybelsus tablets. Like Rybelsus, it is approved for type 2 diabetes, not for weight loss.
Is the semaglutide pill as strong as the shot?+
Far less of each tablet reaches the blood, about 1% to 2% for the Wegovy pill against 89% for the Wegovy shot. The Wegovy label reports the pill and the shot in separate trials, each against placebo, and none of the sources we read compared them head to head.
Is oral semaglutide effective for weight loss?+
In the OASIS 4 trial, adults without diabetes who took the Wegovy pill lost 13.6% of their body weight on average by week 64, against 2.2% on placebo, and everyone also had lifestyle support. Those are group averages from one trial, not a forecast for any one person.
When should I take semaglutide tablets?+
Each label sets exact rules on timing, water and food, and the prescriber or pharmacist explains them with the prescription, so this page does not repeat them. The reason for the rules is absorption: anything else in the stomach gets in the way of SNAC.
How long does it take for semaglutide to work?+
In the blood, semaglutide from a tablet peaks about an hour after it is swallowed. Because it stays around for about a week, levels keep building for 4 to 5 weeks before they settle, according to the Rybelsus and Ozempic tablets label. Weight results in OASIS 4 were measured at week 64, so the trial does not say how soon any one person might notice a change.
Can Rybelsus be used for weight loss?+
Not as an approved use. As of 8 November 2026, Rybelsus and Ozempic tablets are approved for type 2 diabetes and heart risk in some of those adults. The semaglutide tablet approved for weight is the Wegovy pill, and that choice belongs with a prescriber.
Sources: Drugs@FDA record for NDA 218316; Novo Nordisk news, US launch, 5 January 2026; FDA news release on Foundayo, 1 April 2026; Drugs@FDA record for NDA 213051; Novo Nordisk news, Ozempic tablets name, 4 February 2026; Wegovy pill and shot label, FDA, June 2026; OASIS 4, New England Journal of Medicine 2025; Rybelsus and Ozempic tablets label, FDA, January 2026
What did we learn about oral semaglutide?
Oral semaglutide is the shot's molecule with a different way in. SNAC calms the acid next to the tablet, lab studies suggest it may blunt pepsin, and it is thought to briefly loosen the stomach lining. Then albumin and the DPP-4 shield keep the small share that gets in working for days. Three brand names sit on top of that one idea, split between diabetes and weight.
Molecule Mechanics is an animated YouTube series that teaches how peptide drugs act, where they came from and what trials found. No episode tells a viewer which medicine to use or where one comes from. ElevenLabs software voices the narration, the animation is original, and every episode lists its sources in the description. This is episode 3, after tirzepatide and cagrilintide.
The cagrilintide episode ended by promising retatrutide, an experimental drug built for three receptors. Our retatrutide calculator turns your own stats into a weight timeline. Spotted an error on this page? Our corrections policy explains how to report it.
Browse the full Molecule Mechanics channel
Sources: The oral semaglutide episode on YouTube; Molecule Mechanics on YouTube
This page is for learning, not medical advice. It sums up what FDA labels, published trials and company releases say about oral semaglutide tablets, and whether any prescription drug suits a person is for their own doctor to judge.